An anaylis of Swedish registy databases found that β-blockers reduced all-cause mortality but did reduce combined all-cause mortality or heart failure hospitalization among patients with preserved ejection fraction.
Ledwidge and coauthors conducted a randomized trial among 1374 at-risk patients in Ireland to determine the efficacy of a screening program using brain-type natriuretic peptide (BNP) and collaborative care in reducing newly diagnosed heart failure and prevalence of significant left ventricular systolic/diastolic dysfunction. In an Editorial, Hernandez discusses heart failure prevention.
This randomized clinical trial compares the effects of liraglutide vs placebo on time to death and rehospitalization and on time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level among patients with heart failure and reduced left ventricular ejection fraction (LVEF) of 40% or lower.
You currently have no searches saved.